NASDAQ:TNFA TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis $0.15 +0.01 (+6.57%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.14 0.00 (-2.05%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About TNF Pharmaceuticals Stock (NASDAQ:TNFA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TNF Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.13▼$0.1550-Day Range$0.14▼$0.2852-Week Range$0.13▼$2.16Volume1.45 million shsAverage Volume1.33 million shsMarket Capitalization$2.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Read More… Receive TNFA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TNF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TNFA Stock News HeadlinesTNF Pharmaceuticals Amends Bylaws to Alter Voting RulesMay 9, 2025 | tipranks.comTNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 AgonistsMay 8, 2025 | businesswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 17, 2025 | Brownstone Research (Ad)TNF Pharmaceuticals uses AI to refine patient selection for trialsApril 24, 2025 | uk.investing.comTNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug DevelopmentApril 22, 2025 | finance.yahoo.comTNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays BearishApril 22, 2025 | msn.comTNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025April 17, 2025 | finance.yahoo.comTNF Pharmaceuticals, Inc. Common Stock (TNFA) Short InterestApril 3, 2025 | nasdaq.comSee More Headlines TNFA Stock Analysis - Frequently Asked Questions How have TNFA shares performed this year? TNF Pharmaceuticals' stock was trading at $1.15 at the beginning of 2025. Since then, TNFA stock has decreased by 87.3% and is now trading at $0.1460. View the best growth stocks for 2025 here. How were TNF Pharmaceuticals' earnings last quarter? TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.36) earnings per share for the quarter. How do I buy shares of TNF Pharmaceuticals? Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TNF Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI). Company Calendar Last Earnings5/15/2025Today6/16/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNFA CIK1321834 Webtnfpharma.com Phone(856) 848-8698Fax856-848-0269Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4 million Net MarginsN/A Pretax MarginN/A Return on Equity-180.71% Return on Assets-84.27% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.21 per share Price / Book0.02Miscellaneous Outstanding Shares14,184,000Free Float2,722,000Market Cap$2.06 million OptionableN/A Beta2.05 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TNFA) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.